Novo Nordisk's Perfect Storm: Layoffs, Litigation, and a Pipeline Under Scrutiny
Published on 08/18/2026 at 05:52 | Redaktion boerse-global.de
The Danish pharmaceutical giant finds itself fighting on multiple fronts simultaneously. A planned reduction of roughly 5,000 jobs — the largest workforce cut in Danish corporate history — has thrust CEO Mike Doustdar into an unusually public defense of his leadership style. His Monday LinkedIn post, responding directly to criticism from unions and a former company stress ombudsman, marks a notable departure from the executive's typically formal communication channels.
The personnel upheaval lands at a delicate moment for the company's share price. Novo Nordisk shares closed at 38.87 euros yesterday, trailing all major moving averages, with the gap to the 200-day average standing at 3.5 percent. The stock now sits roughly 29 percent below its late-January 52-week high of 54.86 euros — a measure of how far investor confidence has eroded over recent months.
A Legal Escalation in the Weight-Loss Wars
The internal turbulence coincides with an intensifying external battle. Novo Nordisk filed a lawsuit against US rival Eli Lilly on Friday, alleging misleading advertising claims related to obesity treatments. The legal offensive comes as competitive pressure mounts: weekly IQVIA prescription data shows Wegovy scripts slipped 1.1 percent week-over-week to approximately 495,500, while Eli Lilly's Zepbound gained 0.7 percentage points of market share.
Regulatory complications add another layer of uncertainty. The FDA classified its April re-inspection of the Catalent-acquired fill-finish facility in Bloomington, Indiana, as "Official Action Indicated," signaling unacceptable compliance deficiencies. Partner Scholar Rock has since withdrawn the site from its regulatory filings, with the final FDA decision on Apitegromab — originally slated for production at the Bloomington plant — now expected by September 30.
Regulatory scrutiny of this kind is a reminder that compliance failures carry real consequences. For UK employers, workplace safety documentation is a frequent inspection target — and missing or outdated risk assessments can lead to enforcement action. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
Pipeline Disappointments Weigh Heavily
The clinical front has delivered mixed results at best. CagriSema, the experimental therapy, failed to demonstrate superior blood sugar control versus Eli Lilly's Tirzepatide in a head-to-head Type 2 diabetes study. The disappointing data, reported roughly two weeks ago, triggered a 2.7 percent decline in the stock — though the secondary source puts the drop at 2.6 percent. Even an expanded share buyback program announced about three weeks ago failed to stem the bleeding, with shares falling 14.1 percent since that announcement.
Analysts are growing increasingly cautious. Berenberg downgraded the stock from "Buy" to "Hold" on Monday, trimming its price target from 325 to 305 Danish kroner. The rationale: meaningful pipeline progress is needed to justify further valuation premiums in the fiercely competitive obesity market. The shares slipped 1.4 percent yesterday to close at 38.84 euros.
A Multifaceted Investor Dilemma
The company's operational narrative remains curiously bifurcated. Management has raised full-year guidance multiple times — most recently in August — yet analysts greeted the move without surprise. Meanwhile, disappointing second-quarter sales figures for key products and an unresolved US securities lawsuit continue to cast shadows. A federal judge recently allowed portions of claims regarding allegedly misleading statements about the CagriSema REDEFINE 1 study to proceed to further litigation.
Danish market commentators note the home-country C25 index has managed only a 4.1 percent gain this year, lagging European and American benchmarks substantially — weakness largely attributed to Novo Nordisk's struggles.
When companies face internal restructuring and regulatory pressure, workplace safety can slip down the priority list — but that's exactly when risks go unmanaged. Over 37,000 UK businesses rely on a free Health & Safety toolkit covering everything from COSHH to fire safety, helping you protect employees and avoid costly penalties. Get the free Health & Safety Toolkit
The workforce question has evolved into an independent risk factor that investors will monitor closely in coming weeks. Whether Doustdar's direct engagement with critics calms the debate or inflames it further could prove pivotal. With the September 30 FDA decision on Apitegromab looming and the Eli Lilly litigation unresolved, the company faces a critical window to demonstrate it can reclaim lost momentum in the obesity market while managing the most significant internal restructuring in its history.
